{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:09:29Z","timestamp":1789157369777,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T00:00:00Z","timestamp":1786838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002449","name":"Jeju National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinthera.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:45:59Z","timestamp":1789087559000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Phosphodiesterase-5 Inhibitors on Mortality and Clinical Outcomes in Advanced Interstitial Lung Disease with Severe Impairment in Gas Exchange: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","author":[{"given":"Jonghoo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-7037","authenticated-orcid":false,"given":"Jae-Uk","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clinthera.2026.08.010_bib0001","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1164\/rccm.202505-1054ST","article-title":"Approach to the evaluation and management of interstitial lung abnormalities: an Official American Thoracic Society Clinical Statement","volume":"211","author":"Podolanczuk","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.clinthera.2026.08.010_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01200-2024","article-title":"Pulmonary hypertension associated with lung diseases","volume":"64","author":"Shlobin","year":"2024","journal-title":"Eur Respir J."},{"key":"10.1016\/j.clinthera.2026.08.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175801","article-title":"A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats","volume":"951","author":"Zhang","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2026.08.010_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.865065","article-title":"Study on the Mechanism of astragalus polysaccharide in treating pulmonary fibrosis based on ``drug-target-pathway'' network","volume":"13","author":"Bing","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.08.010_bib0005","article-title":"DL-3-n-butylphthalide (NBP) alleviates poststroke cognitive impairment (PSCI) by suppressing neuroinflammation and oxidative stress","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.clinthera.2026.08.010_bib0006","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jpp\/rgae058","article-title":"The mechanism of action of Botrychium (Thunb.) Sw. for prevention of idiopathic pulmonary fibrosis based on 1H-NMR-based metabolomics","volume":"76","author":"Lou","year":"2024","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"10.1016\/j.clinthera.2026.08.010_bib0007","doi-asserted-by":"crossref","first-page":"00272","DOI":"10.1183\/23120541.00272-2022","article-title":"Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need","volume":"8","author":"Dhont","year":"2022","journal-title":"ERJ Open Res"},{"issue":"19","key":"10.1016\/j.clinthera.2026.08.010_bib0008","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.3390\/cells12192394","article-title":"Pulmonary hypertension in interstitial lung disease: updates in disease, diagnosis, and therapeutics","volume":"12","author":"Haynes","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J."},{"key":"10.1016\/j.clinthera.2026.08.010_bib0010","article-title":"5-deoxy-rutaecarpine protects against LPS-induced acute lung injury via inhibiting NLRP3 inflammasome-related inflammation","volume":"16","author":"Luo","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.010_bib0011","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension","volume":"1","author":"Barnes","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.clinthera.2026.08.010_bib0012","first-page":"1203","article-title":"Converging pathways: a review of pulmonary hypertension in interstitial lung disease","volume":"14","author":"Lawrence","year":"2024","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12310","article-title":"Pulmonary hypertension in the setting of interstitial lung disease: approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension","volume":"14","author":"Shlobin","year":"2024","journal-title":"Pulm Circ"},{"key":"10.1016\/j.clinthera.2026.08.010_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.992879","article-title":"PAH-specific therapy for pulmonary hypertension and interstitial lung disease: a systemic review and meta-analysis","volume":"9","author":"Zhao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2026.08.010_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1641932","article-title":"Drugs targeting the NO-sGC-cGMP pathway in the treatment of patients with COPD-associated pulmonary hypertension: a systematic review","volume":"16","author":"Alqarni","year":"2025","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.010_bib0016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1086\/690017","article-title":"Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis","volume":"7","author":"Prins","year":"2017","journal-title":"Pulm Circ"},{"issue":"10","key":"10.1016\/j.clinthera.2026.08.010_bib0017","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1164\/rccm.202412-2371OC","article-title":"Hemodynamics and phosphodiesterase-5 inhibitor treatment associated with survival in pulmonary hypertension in interstitial lung disease: a PVRI GoDeep meta-registry analysis","volume":"211","author":"Yogeswaran","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.clinthera.2026.08.010_bib0018","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.14378","article-title":"Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: a Bayesian retrospective observational cohort study","volume":"28","author":"Dawes","year":"2023","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.clinthera.2026.08.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12273","article-title":"The PH-ILD Detection tool: external validation and use in patients with ILD","volume":"13","author":"Parikh","year":"2023","journal-title":"Pulm Circ"},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/2045894019891912","article-title":"Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea","volume":"10","author":"Zou","year":"2020","journal-title":"Pulm Circ"},{"issue":"7","key":"10.1016\/j.clinthera.2026.08.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clinthera.2026.08.010_bib0022","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2026.08.010_bib0023","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.clinthera.2026.08.010_bib0024","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.clinthera.2026.08.010_bib0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.clinthera.2026.08.010_bib0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clinthera.2026.08.010_bib0027","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"10.1016\/j.clinthera.2026.08.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.010_bib0029","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.010_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","article-title":"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.clinthera.2026.08.010_bib0031","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Zisman","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clinthera.2026.08.010_bib0032","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.010_bib0033","article-title":"Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis","volume":"11","author":"Kang","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.clinthera.2026.08.010_bib0034","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1378\/chest.07-1771","article-title":"The carbon monoxide diffusing capacity: clinical implications, coding, and documentation","volume":"134","author":"Plummer","year":"2008","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.clinthera.2026.08.010_bib0035","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCRESAHA.121.319970","article-title":"Group 3 pulmonary hypertension: from bench to bedside","volume":"130","author":"Singh","year":"2022","journal-title":"Circ Res"},{"issue":"143","key":"10.1016\/j.clinthera.2026.08.010_bib0036","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0053-2016","article-title":"Pulmonary vascular and cardiac impairment in interstitial lung disease","volume":"26","author":"Panagiotou","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.clinthera.2026.08.010_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70210","article-title":"Phenotypic analysis of pulmonary hypertension associated with low diffusion capacity and preserved lung function","volume":"15","author":"Zhao","year":"2025","journal-title":"Pulm Circ."},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.010_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191239","article-title":"Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation\/perfusion matching","volume":"13","author":"Chamorro","year":"2018","journal-title":"PLoS One"},{"issue":"161","key":"10.1016\/j.clinthera.2026.08.010_bib0039","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0059-2021","article-title":"Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome","volume":"30","author":"Gierhardt","year":"2021","journal-title":"Eur Respir Rev"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:30:38Z","timestamp":1789155038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826003115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S0149291826003115"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.08.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Phosphodiesterase-5 Inhibitors on Mortality and Clinical Outcomes in Advanced Interstitial Lung Disease with Severe Impairment in Gas Exchange: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}